Citi cuts Fever-Tree price target, keeps ‘neutral’ rating.


Citi cut its price target on Fever-Tree on Friday to 950p from 1,115p citing slight model changes and an adjustment to its price-to-earnings valuation method.

  • FEVERTREE DRINKS
  • 09 August 2024 09:58:00
FeverTree

Source: Sharecast

The bank maintained its ‘neutral’ rating on the shares into the first-half results.

"Poor weather across much of Europe, particularly in June is likely to have tempered H1 momentum for Fever-Tree," it said.

"While US trading is expected to have been resilient and Rest of World should see a strong rebound on soft destocking comps in Australia, the tougher backdrop in Europe leaves our H1 OSG estimate at +2.1%."

Looking ahead, Citi said it sees better weather across Europe in July as supportive for current trading, while ongoing tailwinds from 2024 pricing and lower freight costs are likely to fall more heavily in the second half.

"As such, with an H2-weighted delivery, we believe FY24E guidance metrics remain intact," it said.


N/A

ISIN: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Created with Highcharts 11.0.1Jan '17Jul '17Jan '18Jul '18Jan '19Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '2512.5k15k17.5k20k22.5k25k27.5k30k32.5k

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.